Mesoblast set for Asian launch
Monday, 16 February, 2009
Melbourne biotech Mesoblast has signed a collaborative program with Singapore’s Parkway Group Healthcare to trial its cartilage stem cell product RepliCart.
RepliCart is aimed at preventing or treating osteoarthritis of the knee, both in the elderly and following knee reconstruction surgery.
Last month, Mesoblast announced it was beginning Phase II trials of RepliCart in people under 40 who had undergone anterior cruciate ligament surgery
The agreement with Parkway Group Healthcare, which operates 15 private hospitals in Asia, involves a single-injection safety and efficacy trial at Parkway’s Clinical Centre of Excellence in Singapore.
Mesoblast said further trials were planned for additional clinical indications.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
